ロード中...
Body composition and aspirin dose for colorectal adenoma prevention in a randomized clinical trial
BACKGROUND: Visceral adiposity is a risk factor for colorectal adenomas, and aspirin is an established chemopreventive agent. Evidence from clinical trials suggests the effectiveness of aspirin at preventing cardiovascular disease and cancer may require higher doses for higher body weight. METHODS:...
保存先:
| 出版年: | Cancer Epidemiol Biomarkers Prev |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6608598/ https://ncbi.nlm.nih.gov/pubmed/31263057 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1055-9965.EPI-19-0205 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|